Coiled Therapeutics (COIL) Stock Overview
A clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
COIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Coiled Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.30 |
| 52 Week Low | UK£0.068 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 33.33% |
| 1 Year Change | -34.64% |
| 3 Year Change | -83.67% |
| 5 Year Change | -85.19% |
| Change since IPO | -85.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| COIL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | 0.6% |
| 1Y | -34.6% | 2.2% | 16.7% |
Return vs Industry: COIL underperformed the UK Biotechs industry which returned 2.2% over the past year.
Return vs Market: COIL underperformed the UK Market which returned 16.7% over the past year.
Price Volatility
| COIL volatility | |
|---|---|
| COIL Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: COIL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: COIL's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sridhar Vempati | www.coiledtx.com/ |
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials.
Coiled Therapeutics plc Fundamentals Summary
| COIL fundamental statistics | |
|---|---|
| Market cap | UK£42.59m |
| Earnings (TTM) | UK£0 |
| Revenue (TTM) | n/a |
Is COIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COIL income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£0 |
| Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did COIL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 00:59 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coiled Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.